Lipoprotein (a) is a cholesterol-rich plasma lipoprotein with a lipid composition similar to that of low-density lipoproteins (LDL). Many prospective and case-control studies identified elevated levels of lipoprotein (a) as a risk factor for premature myocardial infarction and stroke. Elevated lipoprotein (a) has been identified as a genetically determined risk factor for stroke in young adults, but only preliminary data are available on its role as a risk factor for ischemic stroke in infants and children.
Introduction
Childhood stroke is increasingly recognized as an important cause of morbidity and mortality. Incidence estimates vary, depending on definitions and inclusion criteria, and range from 2 to 13 per 100 000 children younger than 18 years of age per year in North America and Europe, with a majority of authors finding an incidence of approximately 3 per 100 000 children per year. [1] [2] [3] [4] Prothrombotic risk factors represent one of the most confusing areas in childhood stroke literature. Small case series and case-control studies have linked childhood arterial ischemic stroke (AIS) and various prothrombotic risk factors, including elevations in homocysteine and lipoprotein (a) [lip (a)], deficiency of natural anticoagulants protein C, protein S, and antithrombin III, and the presence of the factor V Leiden G1691A mutation as well as the prothrombin (PT) gene mutation G20210A. 5, 6 Lipoprotein (a) is a cholesterol-rich plasma lipoprotein with a lipid composition similar to that of low-density lipoproteins (LDL). The protein composition is different from that of LDL, consisting of 2 major proteins, apolipoprotein (apo) B and apo (a). 7, 8 The homology of segments of apolipoprotein (a) to the fibrin-binding sites of plasminogen is thought to be responsible for the antifibrinolytic activities of lip (a). In vitro studies show that lip (a) competes with plasminogen for binding sites on a specific endothelial cell receptor and may interfere with endogenous endothelial cell-mediated fibrinolysis. Lip (a) also binds and inactivates tissue factor pathway inhibitor. 9 Many prospective and case-control studies identified elevated levels of lip (a) as a risk factor for premature myocardial infarction and stroke. [10] [11] [12] Elevated lip (a) has been identified as a genetically determined risk factor for stroke in young adults, but only preliminary data are available on its role as a risk factor for ischemic stroke in infants and children. 13, 14 Raised lip (a) levels were also found to be related to increased risk of recurrent ischemic stroke. 15 From the Divisions of Pediatric Neurology (ST, GD), Division of Pediatric Molecular Pathology (NA), and Laboratory of Biochemistry (KS), University of Ankara Faculty of Medicine, Ankara, Turkey.
The current case-control study was undertaken to investigate whether elevated lip (a) levels are associated with increased risk of ischemic stroke.
Material and Method
From January 1992 to February 2006, 52 consecutive patients were referred to Pediatric Neurology Department of Ankara University with the diagnosis of AIS. A total of 21 girls (40.4%) and 31 boys (59.6%) with mean symptom age 3.24 + 4.35 years (range: 0-15 years old) followed up in our institution for at least 2 years (mean, 5.29 + 4.26 years; range, 2-17 years) are included in the study. The mean age during the time of study was 5.96 + 4.85 years (range: 0.1-18 years). Neuroimaging (hypodensity on computed cranial tomographic scan or hyposignal on T1-weighted and hypersignal on T2-weighted magnetic resonance imaging) and magnetic resonance angiography were used to confirm the diagnosis of AIS.
For determining the risk factors of stroke, whole blood count, biochemical analysis, lipid profile, echocardiography, metabolic screening including urine and blood aminoacids, lactate, and hemoglobin electrophoresis were performed.
With informed parental consent, samples from 78 age-and sex-matched children who have no history of stroke or chronic illness from the same geographic areas were investigated as controls. The present case-control study was performed in accordance with the ethical standards and approved by the medical ethics committee.
Lip (a) was studied by ''particle enhanced'' immunonephlometric assay, the reference range was 0-30 ng/mL. To prevent confounding effects of acute reactive processes, 3 to 6 months had to pass between the thrombotic episode and blood sample collection for the analysis of lip (a). Patients with abnormal quantitative laboratory test results were reanalyzed 1 month later.
For genetic analysis, venous blood was obtained in EDTA-treated sample tubes. The FV Leiden G1691A, PT G20210A, and MTHFR C677T genotypes were determined by polymerase chain reaction and analysis of restriction fragments as previously reported. 16 Factors VIII and IX were studied with 1-stage clotting assay, Von Willebrand factor (VWf) was studied with immunoturbidometric assay. Proteins C and S were measured with commercially available enzyme-linked immunosorbent assay kits. For homocysteine, after 12 hours fasting, blood specimens with EDTA were drawn and measured using AxSYM homocystein assay (Abbot, Wiesbaden, Germany).
The statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS-X). The relation between age and sex in controls and patient group were analyzed by chi-square and Mann-Whitney test. Data of lip (a) are presented as medians, and the relationship between groups were evaluated with Mann-Whitney test.
Results
A total of 52 patients with ischemic stroke were studied; 34 (65%) patients showed infarcts in middle cerebral artery territory, 5 (10%) of them in posterior cerebral artery territory, and 13 (25%) had ischemic lesion on deeper brain regions. They had a follow-up period of at least 2 years from the time they were diagnosed with ischemic cerebral infarct. One patient with moyamoya disease and 1 patient with only high lip (a) level had recurrent stroke. The underlying diseases were encephalitis in 3 patients, congenital heart disease in 6 patients, moyamoya disease in 2 patients, varicella infection in 1 patient, leukemia in 1 patient, phenylketonuria in 1 patient, neuroblastoma with central nervous system (CNS) involvement in 1 patient, and congenital adrenal hyperplasia in 1 patient. There were no patient with diabetes or hypertension, but 2 patients had hyperlipidemia (their lip (a) levels were: 13.1 and 10 mg/dL, respectively) and 2 patients had polycythemia associated with congenital heart disease. In addition, metabolic screening such as urine and blood aminoacids, lactate, and hemoglobin electrophoresis for hemoglobinopathies was normal in all patients ( Table 1) .
The median value of lip (a) level was 11.85 (range: 1.90-140) in the AIS group and 6.02 (range: 0.64-76.8) in the age-matched control group (P < .05). In the stroke group, there were 14 (26.9%) patients who had lip (a) level higher than the cutoff level of 30 mg/dL and in the control group there were 10 (12.8%) patients who had lip (a) level higher than the cutoff level of 30 mg/dL (P < .05). The odds ratio (OR) for lip (a) greater than 30 mg/dL was 2.5 (95% confidence interval [CI]: 1.05-6.183) for ischemic stroke. When markedly elevated cutoff level of 50 mg/dL was chosen in this study, 9.6% of patients with stroke and 2.5% of the controls had lip (a) levels higher than 50 mg/dL. There was no patient in the control group who had a lip (a) level higher than 100 mg/dL, but there were 3 (5.7%) patients in the stroke group ( Table 2) .
The thrombophilia workup was performed in all patients; homocysteine level, factors VIII and IX levels, mutations for factor V Leiden, PT G20210A, methylenetetrahydrofolate reductase (MTHFR) C677T, protein C and protein S activity, antithrombin III level, antiphospholipid antibodies, and anticardiolipin antibodies were determined. Of the 52 children, 7 (13.5%) showed the factor V Leiden mutation, 17 (32.7%) MTHFR C677T mutation, 1 (2%) PT G20210A mutation, 9 (17.3%) protein C deficiency, 5 (9.6%) protein S deficiency, 18 (34.6%) increased factor VIII level, 7 (13.5%) increased factor IX level, and 1 (2%) antithrombin III deficiency. Hyperhomocysteinemia was found in 10 patients (19.2%) with AIS. None of the 52 children showed primary antiphospholipid syndrome. Two children with increased lip (a) were heterozygous for the factor V Leiden mutation, 3 children were heterozygous for MTHFR C677T mutation, 1 child was homozygote for MTHFR C677T mutation, 5 children had increased factor VIII level, 1 child had increased factor IX level, 3 children had protein C deficiency, and 4 children showed hyperhomocysteinemia with increased lip (a). The thrombophilic risk factors were not different between the stroke patients with either high or normal lip (a) levels (P > .05; Table 3 ).
None of the patients had died during the followup period, but the patient who had a lip (a) level of 66 mg/dL had 3 recurrences of stroke.
Discussion
Data of this study indicate that 26.9% of children with AIS had high lip (a) levels in comparison with the age-matched healthy control group. Especially the lip (a) levels higher than 50 and 100 mg/dL were more common in the stroke group.
In vitro studies show that lip (a) competes with plasminogen for binding sites on a specific endothelial cell receptor and may interfere with endogenous endothelial cell-mediated fibrinolysis. Lip (a) also binds and inactivates tissue factor pathway inhibitor. 9 Lip (a) has previously been identified as an independent risk factor for both myocardial infarction and atherothrombotic stroke in young adults. [10] [11] [12] Elevated lip (a) has been identified as a genetically determined risk factor for stroke in young adults, but few data are available on its role as a risk factor for ischemic stroke in infants and children. It has been shown to be a risk factor for arterial and venous thrombosis in childhood as well as for porencephaly and peripartal stroke in neonates. [13] [14] [15] [16] [17] [18] It was also found that the relative risk of having a second stroke was significantly increased in children with raised lip (a) levels. 16 One of our patients who had a lip (a) level of 66 mg/dL and had no other prothrombotic risk factor had 3 recurrences of stroke.
We also have 2 male patients with venous thromboembolism related to Behçet's disease who are not included to this study and who have high levels of lip (a). The relationship between high lip (a) and vascular events in Behcet's disease is well established. 19, 20 
Conclusion
Measurement of lip (a) should be included in screening programs performed in young patients suffering not only from venous thromboembolism but also from AIS, in addition to other thrombophilic factors. For reprints and permissions queries, please visit SAGE's Web site at http://www.sagepub.com/journalsPermissions.nav. 
